Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome -- Ignore unavailable to you. Want to Upgrade?

To: Gary Mohilner who wrote (628)	7/2/1998 10:13:00 AM
From: Beltropolis Boy	Respond to of 900

The Liposome Company Receives Expanded Labeling for ABELCET(R) in Sweden July 2, 1998 08:15 AM PRINCETON, N.J., July 2 /PRNewswire/ -- The Swedish regulatory authority has cleared ABELCET(R) for expanded use in the first-line treatment of candidiasis. This is in addition to the June 1996 approval to market ABELCET(R) in Sweden for the treatment of severe, invasive fungal infections in patients who have not responded to or are intolerant of conventional amphotericin B or other systemic antifungal therapy. ABELCET(R) (Amphotericin B Lipid Complex Injection), is a proprietary drug developed by The Liposome Company, Inc. LIPO and marketed in Sweden and six other European countries by Wyeth-Ayerst International, a subsidiary of American Home Products. Candidiasis is the most common type of invasive fungal infection, representing approximately 70 percent of all such infections. The Candida fungus that causes this infection is rapidly disposed of by a healthy individual's immune system. However, patients with suppressed immune systems, most often resulting from the treatments for cancer, bone marrow transplants and AIDS, can lose the ability to combat fungi such as Candida. The resulting infections can be fatal. The Liposome Company is a biopharmaceutical company developing and marketing therapeutic products to treat cancer and related diseases. ABELCET(R), which has been approved in 19 countries, is marketed in the United States for the treatment of severe, systemic fungal infections in patients who are refractory to or intolerant of conventional therapy and is the leading lipid-based formulation of amphotericin B in this country. Preparations are underway to file a New Drug Application in the U.S. for the Company's second drug, EVACET(TM) (formerly TLC D-99), liposomal doxorubicin, as a treatment for metastatic breast cancer. The Company's product pipeline includes TLC ELL-12 and bromotaxol for the treatment of various cancers, programs focused on the development of new cancer therapies and vehicles for the delivery of gene therapy. investor.msn.com